We apologize for a recent technical issue where emails were triggered to some accounts. Please disregard the emails and know we are promptly working on resolving the issue. Thank you for your understanding and patience.
FDA Approves Orserdu for ER+ MBC (oral SERD)
moderators
Posts: 9,647
FDA Approves Orserdu for Metastatic, Estrogen Receptor-Positive Breast Cancer
Jan 27, 2023
The FDA has approved Orserdu, a new oral medicine to treat metastatic, estrogen receptor-positive, HER2-negative breast cancer with an ESR1 mutation. Read more....
0
Categories
Join Us on Zoom: Upcoming virtual support groups. Read more...
Share more about you! Fill out your NEW profile.